ESMO 2024
PULMÓN
ESTADIO TEMPRANO
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Evaluation of safety and feasibility of adjuvant
chemotherapy in elderly patients with primary non-small
cell lung cancer
1224P
Neoadjuvant Tislelizumab (TIS) Plus Chemotherapy (CT)
with Adjuvant TIS vs. Neoadjuvant Placebo (PBO) Plus CT
with Adjuvant PBO in Resectable Non-Small Cell Lung
Cancer (NSCLC): Patient-Reported Outcomes (PRO) in the
RATIONALE-315 Trial
1213P
Neoadjuvant nivolumab and nivolumab+ipilimumab in
resectable non-small cell lung cancer: Combined analysis of
5-year outcomes from NEOSTAR and CA209-159
1209P
Trial in Progress: Combining Immunotherapy with Trop2
ADc in Early stage non-small cell Lung cancer (CITADEL)
1238TiP
NEO-PIONEER：Neoadjuvant Hypofractionated Radiotherapy
plus Tislelizumab with Anlotinib Followed by Adjuvant
Tislelizumab with Anlotinib in Patients with Resectable
Non-Small Cell Lung Cancer (NSCLC): A Phase II Trial in
Progress
1239TiP
Neoadjuvant nivolumab monotherapy for high-risk clinical
stage I non-small cell lung cancer: A phase 2 POTENTIAL
study
1207MO
Regístrate aquí para recibir más contenidos
Registrarse
ESMO 2024
PULMÓN
LOCALMENTE AVANZADO O METASTÁSICO
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
MET×MET bispecific antibody davutamig (REGN5093) for
MET-altered advanced non-small cell lung cancer (aNSCLC):
Update from a first-in-human (FIH) study(aNSCLC)
1302P
Risk model for overall survival (OS) based on composite
patient-reported outcomes (PROs) in aNSCLC patients
treated with first-line (1L) cemiplimab-based therapy
1853P
ALINA: exploratory biomarker analyses in patients (pts) with
resected ALK+ non-small cell lung cancer (NSCLC) treated
with adjuvant alectinib vs chemotherapy (chemo)
1206MO
Associations of ctDNA clearance (CL) during neoadjuvant Tx
with pathological response and event-free survival (EFS) in
pts with resectable NSCLC (R-NSCLC): Expanded
analyses from AEGEAN
LBA49
CCTG BR.31: A global, double-blind placebo-controlled,
randomized phase III study of adjuvant durvalumab in
completely resected non-small cell lung cancer (NSCLC)
LBA48
Perioperative nivolumab (NIVO) v placebo (PBO) in patients
(pts) with resectable NSCLC: Clinical update from the phase
III CheckMate 77T study
LBA50
ESTADIO TEMPRANO
Regístrate aquí para recibir más contenidos
Registrarse
ESMO 2024
PULMÓN
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Updated efficacy and safety from the phase II PHAROS
study of encorafenib plus
binimetinib in patients with BRAF V600E-mutant
metastatic NSCLC (mNSCLC)
LBA56
Mechanisms of acquired resistance to first-line
amivantamab plus lazertinib versus osimertinib in patients
with EGFR-mutant advanced non-small cell lung cancer:
An early analysis from the phase III MARIPOSA study
LBA55
Osimertinib (osi) after definitive chemoradiotherapy (CRT)
in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS
and distant progression from the Phase 3 LAURA study
1241MO
Precision immuno-oncology for advanced non-small cell
lung cancer (NSCLC) patients with PD-(L)1 inhibitors
resistance (PIONeeR): A phase Ib/IIa clinical trial targeting
identified resistance pathways
LBA8
Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with
KRASG12C-mutated advanced NSCLC and baseline brain
metastases (BM): Results from KRYSTAL-12
LBA57
ABBV-400 a c-Met protein-targeting antibody-drug
conjugate (ADC), in patients (Pts) with advanced EGFR
wildtype (WT) non-squamous (NSQ) non-small cell lung
cancer (NSCLC): Results from a phase I study
1257MO
LOCALMENTE AVANZADO O METASTÁSICO
Regístrate aquí para recibir más contenidos
Registrarse
ESMO 2024
PULMÓN
OTROS TUMORES DEL TÓRAX
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
PECATI: A phase II trial to evaluate the efficacy and safety
of lenvatinib in combination with pembrolizumab in
pretreated advanced B3-thymoma and thymic carcinoma
LBA83
ARTIMES: Automated Response evaluation to Treatment In
MESothelioma
1910MO
Updated survival and vaccine response from the NIPU trial:
A randomised, phase II study evaluating nivolumab and
ipilimumab with or without UV1 vaccination in patients with
pleural mesothelioma
1917P
Molecular analysis of mesothelioma reveals mutations as
prognostic biomarkers for patients treated with the
combination of ipilimumab and nivolumab
1921P
Nintedanib(N) as switch maintenance treatment in
malignant pleural mesothelioma (MPM) (NEMO): A
double-blind randomized phase II trial (EORTC-08112-LCG)
1914P
Durvalumab (D) as consolidation therapy in limited-stage
SCLC (LS-SCLC): Outcomes by prior concurrent
chemoradiotherapy (cCRT) regimen and prophylactic
cranial irradiation (PCI) use in the ADRIATIC trial
LBA81
LOCALMENTE AVANZADO O METASTÁSICO
Regístrate aquí para recibir más contenidos
Registrarse
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
OVARIO
Datopotamab deruxtecan (Dato-DXd) in patients with
endometrial (EC) or ovarian cancer (OC): results from the
Phase 2 TROPION-PanTumor03 study
714MO
Mirvetuximab Soravtansine (MIRV) in Recurrent
Platinum-Sensitive Ovarian Cancer (PSOC) with High Folate
Receptor-Alpha (FRα) Expression: Results from the PICCOLO
Trial
718MO
Phase 3 MIRASOL Trial: Updated Overall Survival Results of
Mirvetuximab Soravtansine (MIRV) vs. Investigator’s Choice
Chemotherapy (ICC) in Patients (pts) with
Platinum-Resistant Ovarian Cancer (PROC) and High Folate
Receptor-Alpha (FRα) Expression
746P
Final overall survival (OS) from the Phase III
ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz)
versus placebo with standard chemotherapy (Cx) plus
bevacizumab (bev) in ovarian cancer (OC) patients (pts) with
platinum-sensitive relapse (PSR)
712MO
SOLACE2: A Phase 2 randomized trial of Olaparib (O) and
Durvalumab (D) with or without low dose
cyclophosphamide (LDCy) in platinum-sensitive recurrent
ovarian cancer (PSROC)
747P
Regístrate aquí para recibir más contenidos
Registrarse
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
OVARIO
A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in
Patients with Advanced Ovarian or Endometrial Cancer
719MO
ATHENA-COMBO, a phase 3, randomized trial comparing
rucaparib (RUCA) + nivolumab (NIVO) combination therapy
vs RUCA monotherapy as maintenance treatment in
patients (pts) with newly diagnosed ovarian cancer (OC)
LBA30
ICON9: International phase III randomized study to evaluate
the efficacy of maintenance therapy with olaparib and
cediranib or olaparib alone in patients with relapsed
platinum-sensitive ovarian cancer following a response to
platinum-based chemotherapy
LBA33
Outcomes of BRCA and in-house homologous
recombination deficiency (HRD) testing in women with
ovarian and breast cancer: A multicentre registry study
LBA64
Final overall survival (OS) in patients (pts) with newly
diagnosed advanced ovarian cancer (aOC) treated with
niraparib (nir) first-line (1L) maintenance: results from
PRIMA/ENGOT-OV26/GOG-3012
LBA29
Regístrate aquí para recibir más contenidos
Registrarse
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
Regístrate aquí para recibir más contenidos
Registrarse
ENDOMETRIAL
Post-Progression Survival Outcomes in Patients (pts) with
Primary Advanced or Recurrent Endometrial Cancer
(pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
Who Received Follow-up Immunotherapy
731P
Impact of investigator-assessed response on overall survival
(OS) in patients (pts) with primary advanced or recurrent
endometrial cancer (pA/rEC) in the
ENGOT-EN6-NSGO/GOG3031/RUBY trial
734P
Durvalumab + carboplatin/paclitaxel (CP) followed by
durvalumab ± olaparib as a first-line treatment for
endometrial cancer (EC): progression-free survival (PFS) by
clinical factors in DUO-E
732P
Efficacy and safety of sacituzumab govitecan (SG) in
patients with advanced/metastatic endometrial cancer (EC):
updated results from TROPiCS-03
733P
Validation of circulating tumor DNA for prognostication and
monitoring in metastatic endometrial carcinoma: ancillary
results from the phase II randomized GINECO trial UTOLA
730P
Characterization of Tumor Response With Lenvatinib Plus
Pembrolizumab (LEN + Pembro) in the
ENGOT-en9/LEAP-001 Study
737P
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
Regístrate aquí para recibir más contenidos
Registrarse
ENDOMETRIAL
Immunotherapy plus Chemotherapy in the First-line
Treatment for Primary Advanced or Recurrent Endometrial
Cancer: An Extracted Individual Patient Data and Trial-Level
Meta-Analysis
743P
Safety and efficacy of sacituzumab tirumotecan (sac-TMT)
in patients (pts) with previously treated advanced
endometrial carcinoma (EC) and ovarian cancer (OC) from
a phase II study
715MO
ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of
pembrolizumab or placebo in combination with adjuvant
chemotherapy with or without radiotherapy in patients
with newly diagnosed, high-risk endometrial cancer.
LBA28
Comparison of the Idylla™ Microsatellite Instability (MSI)
test with a gold standard MSI test and mismatch repair
immunohistochemistry in endometrial cancer
741P
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
Regístrate aquí para recibir más contenidos
Registrarse
CERVICAL
Long-term patient-reported outcomes (PROs) with
atezolizumab (atezo) + bevacizumab (bev) and
chemotherapy (CT) for metastatic, persistent or recurrent
cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO
68-C/JGOG1084/GOG-3030) randomised phase 3 trial
722P
A phase II study of cadonilimab plus chemotherapy in
persistent recurrent/ metastatic cervical cancer patients
who failed previous immuno/chemotherapy
723P
Chemotherapy plus tislelizumab in young patients with
cervical cancer preserve fertility: a phase II study
728P
Efficacy and Safety of Pembrolizumab plus Olaparib
Combination Therapy in Recurrent Cervical Cancer
Progressed on Platinum-Based Chemotherapy: Results
from the phase II trial of GOTIC-025
726P
Preliminary Outcomes from a Phase 1b/2 Study of the Highly
Potent PI3K-mTOR Dual Inhibitor WX390 Combined with
Toripalimab in Patients with Advanced Cervical Cancer
724P
Treatment of patients with metastatic or relapsed cervical
cancer: results from a quality assurance program of the
AGO Study Group
725P
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
Regístrate aquí para recibir más contenidos
Registrarse
CERVICAL
Induction chemotherapy followed by chemoradiation in
locally advanced cervical cancer: quality of life outcomes of
the GCIG INTERLACE trial.
710MO
Efficacy and Safety of Sacituzumab Tirumotecan
(sac-TMT) Plus Pembrolizumab in Patients with Recurrent
or Metastatic Cervical Cancer
716MO
Primary results from BEATcc (ENGOT-Cx10/GEICO
68-C/JGOG1084/GOG-3030), a randomised phase III trial of
first-line atezolizumab (atezo) combined with a platinum
doublet and bevacizumab (bev) for metastatic (stage IVB),
persistent or recurrent cervical cancer (R/M CC)
VP5-
2023
Pembrolizumab plus chemoradiotherapy for high-risk
locally advanced cervical cancer: Overall survival results
from the randomized, double-blind, phase 3
ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
709O